IDH2 and acute myeloid leukemia: The Agios Pharmaceuticals in association with Celgene has made much progress and their IDHIFA® (AG-221, Enasidenib, compound 1) is the first FDA approved mutant IDH2 selective inhibitor for adult patients with relapsed or refractory acute myeloid leukemia (AML).